oncology
Lung

Neoadjuvant immunotherapy effective in early stage NSCLC: LCMC3


Neoadjuvant treatment with the PD-L1 inhibitor atezolizumab has shown promising results in patients with operable non-small cell lung cancer in an interim analysis of the LCMC3 trial presented at ASCO. Study lead investigator Dr David Kwiatowski, an oncologist at Brigham and Women’s Cancer Center and Dana-Farber Institute, told delegates that immune checkpoint therapy was a ...

Already a member?

Enter your email to keep reading.


OR